SynAct PharmaClinical Stage Biotech Company with focus on Resolution Therapy – A novel approach to fight inflammatory and auto-immune diseases

Lead compound AP1189 in Clinical Phase 2

Press releases

February 26, 2020SynAct Pharma lanserar ny hemsida på engelska
February 12, 2020Korrigering: Bokslutskommuniké 2019 SynAct Pharma AB
February 11, 2020Bokslutskommuniké 2019 SynAct Pharma AB
February 7, 2020SynAct Pharma uppdaterar utvecklingsplaner

All press releases

News

October 28, 2019Redeye: Adding an indication
July 5, 2019Kliniska bevis för behandlingseffekter av melanokortiner vid reumatoid artrit
November 7, 2018Sedermeradagen Stockholm
May 15, 2018Presentation på Sedermeradagen Malmö

Calendar

May 11, 2020Sedermeradagen Malmö
June 8, 2020 - June 11, 2020Bio International Convention
October 8, 2020Sedermeradagen Gothenburg

Subscribe to our press releases